Annual report
4005.TEDINET S100TMMW
Period2023-04-01 → 2024-03-31
Filed2024-06-21
StandardIFRS
ConsolidatedYes
Data checks21 of 21 passed
Key figures · 151
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥2.45T | 2023-04-01 → 2024-03-31 | Cons. | Revenue IFRS |
| Revenue | ¥2.90T | 2022-04-01 → 2023-03-31 | Cons. | Revenue IFRS |
| Revenue | ¥2.77T | 2021-04-01 → 2022-03-31d | Cons. | Revenue IFRS (5-year summary) |
| Revenue | ¥2.29T | 2020-04-01 → 2021-03-31d | Cons. | Revenue IFRS (5-year summary) |
| Revenue | ¥2.23T | 2019-04-01 → 2020-03-31d | Cons. | Revenue IFRS (5-year summary) |
| Operating income | −¥488.8bn | 2023-04-01 → 2024-03-31 | Cons. | Operating profit loss IFRS |
| Operating income | −¥31.0bn | 2022-04-01 → 2023-03-31 | Cons. | Operating profit loss IFRS |
| Profit before tax | −¥462.8bn | 2023-04-01 → 2024-03-31 | Cons. | Profit loss before tax IFRS |
| Profit before tax | ¥231m | 2022-04-01 → 2023-03-31 | Cons. | Profit loss before tax IFRS |
| Profit before tax | ¥251.1bn | 2021-04-01 → 2022-03-31d | Cons. | Profit loss before tax IFRS (5-year summary) |
| Profit before tax | ¥137.8bn | 2020-04-01 → 2021-03-31d | Cons. | Profit loss before tax IFRS (5-year summary) |
| Profit before tax | ¥130.5bn | 2019-04-01 → 2020-03-31d | Cons. | Profit loss before tax IFRS (5-year summary) |
| Net income (owners) | −¥311.8bn | 2023-04-01 → 2024-03-31 | Cons. | Profit loss attributable to owners of parent IFRS |
| Net income (owners) | ¥7.0bn | 2022-04-01 → 2023-03-31 | Cons. | Profit loss attributable to owners of parent IFRS |
| Net income (owners) | ¥162.1bn | 2021-04-01 → 2022-03-31d | Cons. | Profit loss attributable to owners of parent IFRS (5-year summary) |
| Net income (owners) | ¥46.0bn | 2020-04-01 → 2021-03-31d | Cons. | Profit loss attributable to owners of parent IFRS (5-year summary) |
| Net income (owners) | ¥30.9bn | 2019-04-01 → 2020-03-31d | Cons. | Profit loss attributable to owners of parent IFRS (5-year summary) |
| Net income | −¥465.4bn | 2023-04-01 → 2024-03-31 | Cons. | Profit loss IFRS |
| Net income | −¥46.9bn | 2022-04-01 → 2023-03-31 | Cons. | Profit loss IFRS |
| Net income | ¥186.4bn | 2021-04-01 → 2022-03-31d | Cons. | Profit loss IFRS (5-year summary) |
| Net income | ¥68.1bn | 2020-04-01 → 2021-03-31d | Cons. | Profit loss IFRS (5-year summary) |
| Net income | ¥54.4bn | 2019-04-01 → 2020-03-31d | Cons. | Profit loss IFRS (5-year summary) |
| Total assets | ¥3.93T | at 2024-03-31 | Cons. | Assets IFRS |
| Total assets | ¥4.17T | at 2023-03-31 | Cons. | Assets IFRS |
| Total assets | ¥4.31T | at 2022-03-31d | Cons. | Total assets IFRS (5-year summary) |
| Total assets | ¥3.99T | at 2021-03-31d | Cons. | Total assets IFRS (5-year summary) |
| Total assets | ¥3.65T | at 2020-03-31d | Cons. | Total assets IFRS (5-year summary) |
| Total liabilities | ¥2.77T | at 2024-03-31 | Cons. | Liabilities IFRS |
| Total liabilities | ¥2.68T | at 2023-03-31 | Cons. | Liabilities IFRS |
| Net assets / equity | ¥1.16T | at 2024-03-31 | Cons. | Equity IFRS |
| Net assets / equity | ¥1.49T | at 2023-03-31 | Cons. | Equity IFRS |
| Net assets / equity | ¥1.70T | at 2022-03-31d | Cons. | Equity IFRS |
| Equity (owners) | ¥965.8bn | at 2024-03-31 | Cons. | Equity attributable to owners of parent IFRS |
| Equity (owners) | ¥1.17T | at 2023-03-31 | Cons. | Equity attributable to owners of parent IFRS |
| Equity (owners) | ¥1.22T | at 2022-03-31d | Cons. | Equity attributable to owners of parent IFRS (5-year summary) |
| Equity (owners) | ¥1.02T | at 2021-03-31d | Cons. | Equity attributable to owners of parent IFRS (5-year summary) |
| Equity (owners) | ¥924.0bn | at 2020-03-31d | Cons. | Equity attributable to owners of parent IFRS (5-year summary) |
| Cash & equivalents | ¥217.4bn | at 2024-03-31 | Cons. | Cash and cash equivalents IFRS |
| Cash & equivalents | ¥305.8bn | at 2023-03-31 | Cons. | Cash and cash equivalents IFRS |
| Cash & equivalents | ¥365.4bn | at 2022-03-31d | Cons. | Cash and cash equivalents IFRS |
| Cash & equivalents | ¥360.9bn | at 2021-03-31d | Cons. | Cash and cash equivalents IFRS (5-year summary) |
| Cash & equivalents | ¥180.6bn | at 2020-03-31d | Cons. | Cash and cash equivalents IFRS (5-year summary) |
| Operating cash flow | −¥51.3bn | 2023-04-01 → 2024-03-31 | Cons. | Net cash provided by used in operating activities IFRS |
| Operating cash flow | ¥111.6bn | 2022-04-01 → 2023-03-31 | Cons. | Net cash provided by used in operating activities IFRS |
| Operating cash flow | ¥171.7bn | 2021-04-01 → 2022-03-31d | Cons. | Cash flows from used in operating activities IFRS (5-year summary) |
| Operating cash flow | ¥374.5bn | 2020-04-01 → 2021-03-31d | Cons. | Cash flows from used in operating activities IFRS (5-year summary) |
| Operating cash flow | ¥106.0bn | 2019-04-01 → 2020-03-31d | Cons. | Cash flows from used in operating activities IFRS (5-year summary) |
| Investing cash flow | −¥112.2bn | 2023-04-01 → 2024-03-31 | Cons. | Net cash provided by used in investing activities IFRS |
| Investing cash flow | −¥19.4bn | 2022-04-01 → 2023-03-31 | Cons. | Net cash provided by used in investing activities IFRS |
| Investing cash flow | −¥115.4bn | 2021-04-01 → 2022-03-31d | Cons. | Cash flows from used in investing activities IFRS (5-year summary) |
| Investing cash flow | −¥177.4bn | 2020-04-01 → 2021-03-31d | Cons. | Cash flows from used in investing activities IFRS (5-year summary) |
| Investing cash flow | −¥499.7bn | 2019-04-01 → 2020-03-31d | Cons. | Cash flows from used in investing activities IFRS (5-year summary) |
| Financing cash flow | ¥49.2bn | 2023-04-01 → 2024-03-31 | Cons. | Net cash provided by used in financing activities IFRS |
| Financing cash flow | −¥178.5bn | 2022-04-01 → 2023-03-31 | Cons. | Net cash provided by used in financing activities IFRS |
| Financing cash flow | −¥81.4bn | 2021-04-01 → 2022-03-31d | Cons. | Cash flows from used in financing activities IFRS (5-year summary) |
| Financing cash flow | −¥40.0bn | 2020-04-01 → 2021-03-31d | Cons. | Cash flows from used in financing activities IFRS (5-year summary) |
| Financing cash flow | ¥373.5bn | 2019-04-01 → 2020-03-31d | Cons. | Cash flows from used in financing activities IFRS (5-year summary) |
| EPS (basic) | ¥-190.69 | 2023-04-01 → 2024-03-31 | Cons. | Basic earnings loss per share IFRS |
| EPS (basic) | ¥4.27 | 2022-04-01 → 2023-03-31 | Cons. | Basic earnings loss per share IFRS |
| EPS (basic) | ¥99.16 | 2021-04-01 → 2022-03-31d | Cons. | Basic earnings loss per share IFRS (5-year summary) |
| EPS (basic) | ¥28.16 | 2020-04-01 → 2021-03-31d | Cons. | Basic earnings loss per share IFRS (5-year summary) |
| EPS (basic) | ¥18.91 | 2019-04-01 → 2020-03-31d | Cons. | Basic earnings loss per share IFRS (5-year summary) |
| EPS (diluted) | ¥4.27 | 2022-04-01 → 2023-03-31 | Cons. | Diluted earnings loss per share IFRS |
| Net assets per share | ¥590.44 | at 2024-03-31 | Cons. | Equity to asset ratio IFRS (5-year summary) |
| Net assets per share | ¥716.26 | at 2023-03-31 | Cons. | Equity to asset ratio IFRS (5-year summary) |
| Net assets per share | ¥745.03 | at 2022-03-31d | Cons. | Equity to asset ratio IFRS (5-year summary) |
| Net assets per share | ¥623.39 | at 2021-03-31d | Cons. | Equity to asset ratio IFRS (5-year summary) |
| Net assets per share | ¥565.13 | at 2020-03-31d | Cons. | Equity to asset ratio IFRS (5-year summary) |
| Equity ratio | 24.5% | at 2024-03-31 | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
| Equity ratio | 28.1% | at 2023-03-31 | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
| Equity ratio | 28.3% | at 2022-03-31d | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
| Equity ratio | 25.5% | at 2021-03-31d | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
| Equity ratio | 25.3% | at 2020-03-31d | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
| ROE | -29.2% | 2023-04-01 → 2024-03-31 | Cons. | Rate of return on equity IFRS (5-year summary) |
| ROE | 0.6% | 2022-04-01 → 2023-03-31 | Cons. | Rate of return on equity IFRS (5-year summary) |
| ROE | 14.5% | 2021-04-01 → 2022-03-31d | Cons. | Rate of return on equity IFRS (5-year summary) |
| ROE | 4.7% | 2020-04-01 → 2021-03-31d | Cons. | Rate of return on equity IFRS (5-year summary) |
| ROE | 3.2% | 2019-04-01 → 2020-03-31d | Cons. | Rate of return on equity IFRS (5-year summary) |
| Employees | 32,161 | at 2024-03-31 | Cons. | Number of employees |
| Employees | 33,572 | at 2023-03-31 | Cons. | Number of employees |
| Employees | 34,703 | at 2022-03-31d | Cons. | Number of employees |
| Employees | 34,743 | at 2021-03-31d | Cons. | Number of employees |
| Employees | 33,586 | at 2020-03-31d | Cons. | Number of employees |
| Revenue | ¥809.6bn | 2023-04-01 → 2024-03-31 | Standalone | Net sales |
| Revenue | ¥894.4bn | 2022-04-01 → 2023-03-31 | Standalone | Net sales |
| Revenue | ¥797.4bn | 2021-04-01 → 2022-03-31d | Standalone | Net sales (5-year summary) |
| Revenue | ¥646.0bn | 2020-04-01 → 2021-03-31d | Standalone | Net sales (5-year summary) |
| Revenue | ¥678.4bn | 2019-04-01 → 2020-03-31d | Standalone | Net sales (5-year summary) |
| Operating income | ¥2.4bn | 2023-04-01 → 2024-03-31 | Standalone | Operating income |
| Operating income | ¥7.9bn | 2022-04-01 → 2023-03-31 | Standalone | Operating income |
| Ordinary income | ¥53.4bn | 2023-04-01 → 2024-03-31 | Standalone | Ordinary income |
| Ordinary income | ¥69.5bn | 2022-04-01 → 2023-03-31 | Standalone | Ordinary income |
| Ordinary income | ¥68.5bn | 2021-04-01 → 2022-03-31d | Standalone | Ordinary income loss (5-year summary) |
| Ordinary income | ¥38.1bn | 2020-04-01 → 2021-03-31d | Standalone | Ordinary income loss (5-year summary) |
| Ordinary income | ¥28.9bn | 2019-04-01 → 2020-03-31d | Standalone | Ordinary income loss (5-year summary) |
| Profit before tax | ¥10.2bn | 2023-04-01 → 2024-03-31 | Standalone | Income before income taxes |
| Profit before tax | ¥52.5bn | 2022-04-01 → 2023-03-31 | Standalone | Income before income taxes |
| Net income | ¥8.7bn | 2023-04-01 → 2024-03-31 | Standalone | Profit loss |
| Net income | ¥50.4bn | 2022-04-01 → 2023-03-31 | Standalone | Profit loss |
| Net income | ¥61.7bn | 2021-04-01 → 2022-03-31d | Standalone | Net income loss (5-year summary) |
| Net income | ¥41.7bn | 2020-04-01 → 2021-03-31d | Standalone | Net income loss (5-year summary) |
| Net income | ¥22.8bn | 2019-04-01 → 2020-03-31d | Standalone | Net income loss (5-year summary) |
| Total assets | ¥1.90T | at 2024-03-31 | Standalone | Assets |
| Total assets | ¥1.77T | at 2023-03-31 | Standalone | Assets |
| Total assets | ¥1.74T | at 2022-03-31d | Standalone | Total assets (5-year summary) |
| Total assets | ¥1.73T | at 2021-03-31d | Standalone | Total assets (5-year summary) |
| Total assets | ¥1.58T | at 2020-03-31d | Standalone | Total assets (5-year summary) |
| Total liabilities | ¥1.53T | at 2024-03-31 | Standalone | Liabilities |
| Total liabilities | ¥1.39T | at 2023-03-31 | Standalone | Liabilities |
| Net assets / equity | ¥370.4bn | at 2024-03-31 | Standalone | Net assets |
| Net assets / equity | ¥378.0bn | at 2023-03-31 | Standalone | Net assets |
| Net assets / equity | ¥368.8bn | at 2022-03-31d | Standalone | Net assets |
| Net assets / equity | ¥346.2bn | at 2021-03-31d | Standalone | Net assets (5-year summary) |
| Net assets / equity | ¥315.5bn | at 2020-03-31d | Standalone | Net assets (5-year summary) |
| Cash and deposits | ¥69.0bn | at 2024-03-31 | Standalone | Cash and deposits |
| Cash and deposits | ¥5.8bn | at 2023-03-31 | Standalone | Cash and deposits |
| EPS (basic) | ¥5.32 | 2023-04-01 → 2024-03-31 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥30.85 | 2022-04-01 → 2023-03-31 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥37.76 | 2021-04-01 → 2022-03-31d | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥25.52 | 2020-04-01 → 2021-03-31d | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥13.94 | 2019-04-01 → 2020-03-31d | Standalone | Basic earnings loss per share (5-year summary) |
| Dividend per share | ¥9 | 2023-04-01 → 2024-03-31 | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥18 | 2022-04-01 → 2023-03-31 | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥24 | 2021-04-01 → 2022-03-31d | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥15 | 2020-04-01 → 2021-03-31d | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥17 | 2019-04-01 → 2020-03-31d | Standalone | Dividend paid per share (5-year summary) |
| Net assets per share | ¥226.42 | at 2024-03-31 | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥231.14 | at 2023-03-31 | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥225.56 | at 2022-03-31d | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥211.77 | at 2021-03-31d | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥192.95 | at 2020-03-31d | Standalone | Net assets per share (5-year summary) |
| Equity ratio | 19.5% | at 2024-03-31 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 21.3% | at 2023-03-31 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 21.2% | at 2022-03-31d | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 20.0% | at 2021-03-31d | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 20.0% | at 2020-03-31d | Standalone | Equity to asset ratio (5-year summary) |
| ROE | 2.3% | 2023-04-01 → 2024-03-31 | Standalone | Rate of return on equity (5-year summary) |
| ROE | 13.5% | 2022-04-01 → 2023-03-31 | Standalone | Rate of return on equity (5-year summary) |
| ROE | 17.3% | 2021-04-01 → 2022-03-31d | Standalone | Rate of return on equity (5-year summary) |
| ROE | 12.6% | 2020-04-01 → 2021-03-31d | Standalone | Rate of return on equity (5-year summary) |
| ROE | 6.8% | 2019-04-01 → 2020-03-31d | Standalone | Rate of return on equity (5-year summary) |
| Shares issued | 1,656,449,000 | at 2024-03-31 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 1,655,860,000 | at 2023-03-31 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 1,655,446,000 | at 2022-03-31d | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 1,655,446,000 | at 2021-03-31d | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 1,655,446,000 | at 2020-03-31d | Standalone | Total number of issued shares (5-year summary) |
| Employees | 6,706 | at 2024-03-31 | Standalone | Number of employees |
| Employees | 6,637 | at 2023-03-31 | Standalone | Number of employees |
| Employees | 6,488 | at 2022-03-31d | Standalone | Number of employees |
| Employees | 6,277 | at 2021-03-31d | Standalone | Number of employees |
| Employees | 6,214 | at 2020-03-31d | Standalone | Number of employees |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 105
| Segment | Item | Period | Value |
|---|---|---|---|
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | capex | 2023-04-01 → 2024-03-31 | ¥5.2bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | employees | at 2024-03-31 | 2651 pure |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue | 2023-04-01 → 2024-03-31 | ¥153.1bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue external | 2023-04-01 → 2024-03-31 | ¥69.8bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue intersegment | 2023-04-01 → 2024-03-31 | ¥83.3bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | segment assets | at 2024-03-31 | ¥340.4bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | segment profit | 2023-04-01 → 2024-03-31 | ¥8.1bn |
| Reconciling Itemsreconciling | capex | 2023-04-01 → 2024-03-31 | ¥7.7bn |
| Reconciling Itemsreconciling | revenue | 2023-04-01 → 2024-03-31 | −¥112.4bn |
| Reconciling Itemsreconciling | revenue intersegment | 2023-04-01 → 2024-03-31 | −¥112.4bn |
| Reconciling Itemsreconciling | segment assets | at 2024-03-31 | ¥65.9bn |
| Reconciling Itemsreconciling | segment profit | 2023-04-01 → 2024-03-31 | −¥16.1bn |
| Energy And Functional Materialsreportable segment | capex | 2023-04-01 → 2024-03-31 | ¥23.8bn |
| Energy And Functional Materialsreportable segment | employees | at 2024-03-31 | 3025 pure |
| Energy And Functional Materialsreportable segment | revenue | 2023-04-01 → 2024-03-31 | ¥317.4bn |
| Energy And Functional Materialsreportable segment | revenue external | 2023-04-01 → 2024-03-31 | ¥300.3bn |
| Energy And Functional Materialsreportable segment | revenue intersegment | 2023-04-01 → 2024-03-31 | ¥17.1bn |
| Energy And Functional Materialsreportable segment | segment assets | at 2024-03-31 | ¥347.3bn |
| Energy And Functional Materialsreportable segment | segment profit | 2023-04-01 → 2024-03-31 | ¥7.8bn |
| Essential Chemicals And Plasticsreportable segment | capex | 2023-04-01 → 2024-03-31 | ¥26.9bn |
| Essential Chemicals And Plasticsreportable segment | employees | at 2024-03-31 | 4068 pure |
| Essential Chemicals And Plasticsreportable segment | revenue | 2023-04-01 → 2024-03-31 | ¥779.4bn |
| Essential Chemicals And Plasticsreportable segment | revenue external | 2023-04-01 → 2024-03-31 | ¥774.0bn |
| Essential Chemicals And Plasticsreportable segment | revenue intersegment | 2023-04-01 → 2024-03-31 | ¥5.5bn |
| Essential Chemicals And Plasticsreportable segment | segment assets | at 2024-03-31 | ¥850.4bn |
| Essential Chemicals And Plasticsreportable segment | segment profit | 2023-04-01 → 2024-03-31 | −¥90.7bn |
| Health And Agriculture Relatedreportable segment | capex | 2023-04-01 → 2024-03-31 | ¥31.0bn |
| Health And Agriculture Relatedreportable segment | employees | at 2024-03-31 | 7899 pure |
| Health And Agriculture Relatedreportable segment | revenue | 2023-04-01 → 2024-03-31 | ¥552.0bn |
| Health And Agriculture Relatedreportable segment | revenue external | 2023-04-01 → 2024-03-31 | ¥546.0bn |
| Health And Agriculture Relatedreportable segment | revenue intersegment | 2023-04-01 → 2024-03-31 | ¥6.0bn |
| Health And Agriculture Relatedreportable segment | segment assets | at 2024-03-31 | ¥903.8bn |
| Health And Agriculture Relatedreportable segment | segment profit | 2023-04-01 → 2024-03-31 | ¥30.9bn |
| Information Electronic Chemistryreportable segment | capex | 2023-04-01 → 2024-03-31 | ¥42.9bn |
| Information Electronic Chemistryreportable segment | employees | at 2024-03-31 | 7437 pure |
| Information Electronic Chemistryreportable segment | revenue | 2023-04-01 → 2024-03-31 | ¥414.6bn |
| Information Electronic Chemistryreportable segment | revenue external | 2023-04-01 → 2024-03-31 | ¥414.1bn |
| Information Electronic Chemistryreportable segment | revenue intersegment | 2023-04-01 → 2024-03-31 | ¥454m |
| Information Electronic Chemistryreportable segment | segment assets | at 2024-03-31 | ¥465.2bn |
| Information Electronic Chemistryreportable segment | segment profit | 2023-04-01 → 2024-03-31 | ¥44.0bn |
| Medical Productsreportable segment | capex | 2023-04-01 → 2024-03-31 | ¥20.9bn |
| Medical Productsreportable segment | employees | at 2024-03-31 | 5727 pure |
| Medical Productsreportable segment | revenue | 2023-04-01 → 2024-03-31 | ¥342.7bn |
| Medical Productsreportable segment | revenue external | 2023-04-01 → 2024-03-31 | ¥342.7bn |
| Medical Productsreportable segment | revenue intersegment | 2023-04-01 → 2024-03-31 | ¥3m |
| Medical Productsreportable segment | segment assets | at 2024-03-31 | ¥961.9bn |
| Medical Productsreportable segment | segment profit | 2023-04-01 → 2024-03-31 | −¥133.0bn |
| —segment total | capex | 2023-04-01 → 2024-03-31 | ¥145.5bn |
| —segment total | revenue | 2023-04-01 → 2024-03-31 | ¥2.41T |
| —segment total | revenue external | 2023-04-01 → 2024-03-31 | ¥2.38T |
| —segment total | revenue intersegment | 2023-04-01 → 2024-03-31 | ¥29.1bn |
| —segment total | segment assets | at 2024-03-31 | ¥3.53T |
| —segment total | segment profit | 2023-04-01 → 2024-03-31 | −¥141.0bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | capex | 2022-04-01 → 2023-03-31 | ¥6.6bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue | 2022-04-01 → 2023-03-31 | ¥172.7bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue external | 2022-04-01 → 2023-03-31 | ¥85.4bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue intersegment | 2022-04-01 → 2023-03-31 | ¥87.3bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | segment assets | at 2023-03-31 | ¥371.7bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | segment profit | 2022-04-01 → 2023-03-31 | ¥10.4bn |
| Reconciling Itemsreconciling | capex | 2022-04-01 → 2023-03-31 | ¥6.4bn |
| Reconciling Itemsreconciling | revenue | 2022-04-01 → 2023-03-31 | −¥116.6bn |
| Reconciling Itemsreconciling | revenue intersegment | 2022-04-01 → 2023-03-31 | −¥116.6bn |
| Reconciling Itemsreconciling | segment assets | at 2023-03-31 | ¥13.0bn |
| Reconciling Itemsreconciling | segment profit | 2022-04-01 → 2023-03-31 | −¥19.7bn |
| Energy And Functional Materialsreportable segment | capex | 2022-04-01 → 2023-03-31 | ¥26.6bn |
| Energy And Functional Materialsreportable segment | revenue | 2022-04-01 → 2023-03-31 | ¥359.9bn |
| Energy And Functional Materialsreportable segment | revenue external | 2022-04-01 → 2023-03-31 | ¥342.5bn |
| Energy And Functional Materialsreportable segment | revenue intersegment | 2022-04-01 → 2023-03-31 | ¥17.5bn |
| Energy And Functional Materialsreportable segment | segment assets | at 2023-03-31 | ¥380.2bn |
| Energy And Functional Materialsreportable segment | segment profit | 2022-04-01 → 2023-03-31 | ¥15.2bn |
| Essential Chemicals And Plasticsreportable segment | capex | 2022-04-01 → 2023-03-31 | ¥30.2bn |
| Essential Chemicals And Plasticsreportable segment | revenue | 2022-04-01 → 2023-03-31 | ¥858.6bn |
| Essential Chemicals And Plasticsreportable segment | revenue external | 2022-04-01 → 2023-03-31 | ¥852.9bn |
| Essential Chemicals And Plasticsreportable segment | revenue intersegment | 2022-04-01 → 2023-03-31 | ¥5.7bn |
| Essential Chemicals And Plasticsreportable segment | segment assets | at 2023-03-31 | ¥872.6bn |
| Essential Chemicals And Plasticsreportable segment | segment profit | 2022-04-01 → 2023-03-31 | −¥34.2bn |
| Health And Agriculture Relatedreportable segment | capex | 2022-04-01 → 2023-03-31 | ¥24.3bn |
| Health And Agriculture Relatedreportable segment | revenue | 2022-04-01 → 2023-03-31 | ¥604.0bn |
| Health And Agriculture Relatedreportable segment | revenue external | 2022-04-01 → 2023-03-31 | ¥598.4bn |
| Health And Agriculture Relatedreportable segment | revenue intersegment | 2022-04-01 → 2023-03-31 | ¥5.7bn |
| Health And Agriculture Relatedreportable segment | segment assets | at 2023-03-31 | ¥874.0bn |
| Health And Agriculture Relatedreportable segment | segment profit | 2022-04-01 → 2023-03-31 | ¥57.3bn |
| Information Electronic Chemistryreportable segment | capex | 2022-04-01 → 2023-03-31 | ¥32.8bn |
| Information Electronic Chemistryreportable segment | revenue | 2022-04-01 → 2023-03-31 | ¥431.7bn |
| Information Electronic Chemistryreportable segment | revenue external | 2022-04-01 → 2023-03-31 | ¥431.2bn |
| Information Electronic Chemistryreportable segment | revenue intersegment | 2022-04-01 → 2023-03-31 | ¥465m |
| Information Electronic Chemistryreportable segment | segment assets | at 2023-03-31 | ¥464.6bn |
| Information Electronic Chemistryreportable segment | segment profit | 2022-04-01 → 2023-03-31 | ¥47.6bn |
| Medical Productsreportable segment | capex | 2022-04-01 → 2023-03-31 | ¥14.1bn |
| Medical Productsreportable segment | revenue | 2022-04-01 → 2023-03-31 | ¥584.9bn |
| Medical Productsreportable segment | revenue external | 2022-04-01 → 2023-03-31 | ¥584.9bn |
| Medical Productsreportable segment | revenue intersegment | 2022-04-01 → 2023-03-31 | ¥15m |
| Medical Productsreportable segment | segment assets | at 2023-03-31 | ¥1.19T |
| Medical Productsreportable segment | segment profit | 2022-04-01 → 2023-03-31 | ¥16.2bn |
| —segment total | capex | 2022-04-01 → 2023-03-31 | ¥128.0bn |
| —segment total | revenue | 2022-04-01 → 2023-03-31 | ¥2.84T |
| —segment total | revenue external | 2022-04-01 → 2023-03-31 | ¥2.81T |
| —segment total | revenue intersegment | 2022-04-01 → 2023-03-31 | ¥29.3bn |
| —segment total | segment assets | at 2023-03-31 | ¥3.78T |
| —segment total | segment profit | 2022-04-01 → 2023-03-31 | ¥102.1bn |
| Energy And Functional Materialsreportable segment | employees | at 2024-03-31 | 1007 pure |
| Essential Chemicals And Plasticsreportable segment | employees | at 2024-03-31 | 1312 pure |
| Health And Agriculture Relatedreportable segment | employees | at 2024-03-31 | 2025 pure |
| Information Electronic Chemistryreportable segment | employees | at 2024-03-31 | 1043 pure |
| Medical Productsreportable segment | employees | at 2024-03-31 | 22 pure |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 2,789
| Item | Context | Value | Unit |
|---|---|---|---|
| Price earnings ratio IFRS (5-year summary) | Prior1YearDuration | 104.22 | |
| Price earnings ratio IFRS (5-year summary) | CurrentYearDuration | － | |
| Cash flows from used in operating activities IFRS (5-year summary) | Prior4YearDuration | 106012000000 | JPY |
| Cash flows from used in operating activities IFRS (5-year summary) | Prior3YearDuration | 374464000000 | JPY |
| Cash flows from used in operating activities IFRS (5-year summary) | Prior2YearDuration | 171715000000 | JPY |
| Cash flows from used in operating activities IFRS (5-year summary) | Prior1YearDuration | 111621000000 | JPY |
| Cash flows from used in operating activities IFRS (5-year summary) | CurrentYearDuration | -51317000000 | JPY |
| Cash flows from used in investing activities IFRS (5-year summary) | Prior4YearDuration | -499670000000 | JPY |
| Cash flows from used in investing activities IFRS (5-year summary) | Prior3YearDuration | -177389000000 | JPY |
| Cash flows from used in investing activities IFRS (5-year summary) | Prior2YearDuration | -115421000000 | JPY |
| Cash flows from used in investing activities IFRS (5-year summary) | Prior1YearDuration | -19411000000 | JPY |
| Cash flows from used in investing activities IFRS (5-year summary) | CurrentYearDuration | -112240000000 | JPY |
| Cash flows from used in financing activities IFRS (5-year summary) | Prior4YearDuration | 373542000000 | JPY |
| Cash flows from used in financing activities IFRS (5-year summary) | Prior3YearDuration | -39974000000 | JPY |
| Cash flows from used in financing activities IFRS (5-year summary) | Prior2YearDuration | -81394000000 | JPY |
| Cash flows from used in financing activities IFRS (5-year summary) | Prior1YearDuration | -178502000000 | JPY |
| Cash flows from used in financing activities IFRS (5-year summary) | CurrentYearDuration | 49246000000 | JPY |
| Cash and cash equivalents IFRS (5-year summary) | Prior4YearInstant | 180648000000 | JPY |
| Cash and cash equivalents IFRS (5-year summary) | Prior3YearInstant | 360918000000 | JPY |
| Cash and cash equivalents IFRS (5-year summary) | Prior2YearInstant | 365429000000 | JPY |
| Cash and cash equivalents IFRS (5-year summary) | Prior1YearInstant | 305844000000 | JPY |
| Cash and cash equivalents IFRS (5-year summary) | CurrentYearInstant | 217449000000 | JPY |
| Number of employees | Prior4YearInstant | 33586 | |
| Number of employees | Prior3YearInstant | 34743 | |
| Number of employees | Prior2YearInstant | 34703 | |
| Number of employees | Prior1YearInstant | 33572 | |
| Number of employees | CurrentYearInstant | 32161 | |
| Average number of temporary workers | Prior4YearInstant | 3867 | |
| Average number of temporary workers | Prior3YearInstant | 3905 | |
| Average number of temporary workers | Prior2YearInstant | 3814 | |
| Average number of temporary workers | Prior1YearInstant | 3663 | |
| Average number of temporary workers | CurrentYearInstant | 3492 | |
| Net sales (5-year summary) | Prior4YearDuration_NonConsolidatedMember | 678436000000 | JPY |
| Net sales (5-year summary) | Prior3YearDuration_NonConsolidatedMember | 645996000000 | JPY |
| Net sales (5-year summary) | Prior2YearDuration_NonConsolidatedMember | 797358000000 | JPY |
| Net sales (5-year summary) | Prior1YearDuration_NonConsolidatedMember | 894389000000 | JPY |
| Net sales (5-year summary) | CurrentYearDuration_NonConsolidatedMember | 809559000000 | JPY |
| Ordinary income loss (5-year summary) | Prior4YearDuration_NonConsolidatedMember | 28869000000 | JPY |
| Ordinary income loss (5-year summary) | Prior3YearDuration_NonConsolidatedMember | 38089000000 | JPY |
| Ordinary income loss (5-year summary) | Prior2YearDuration_NonConsolidatedMember | 68488000000 | JPY |
| Ordinary income loss (5-year summary) | Prior1YearDuration_NonConsolidatedMember | 69529000000 | JPY |
| Ordinary income loss (5-year summary) | CurrentYearDuration_NonConsolidatedMember | 53425000000 | JPY |
| Net income loss (5-year summary) | Prior4YearDuration_NonConsolidatedMember | 22784000000 | JPY |
| Net income loss (5-year summary) | Prior3YearDuration_NonConsolidatedMember | 41719000000 | JPY |
| Net income loss (5-year summary) | Prior2YearDuration_NonConsolidatedMember | 61736000000 | JPY |
| Net income loss (5-year summary) | Prior1YearDuration_NonConsolidatedMember | 50444000000 | JPY |
| Net income loss (5-year summary) | CurrentYearDuration_NonConsolidatedMember | 8704000000 | JPY |
| Capital stock (5-year summary) | Prior4YearInstant_NonConsolidatedMember | 89699000000 | JPY |
| Capital stock (5-year summary) | Prior3YearInstant_NonConsolidatedMember | 89699000000 | JPY |
| Capital stock (5-year summary) | Prior2YearInstant_NonConsolidatedMember | 89699000000 | JPY |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 21 of 21 passed
| balance sheet identity | pass |
| balance sheet identity | pass |
| balance sheet identity | pass rounding |
| balance sheet identity | pass rounding |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |